Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer

Epigenetics

Volumn 7, Issue 7, 2012, Pages 710-719

  Brait, Mariana ^a   Loyo, Myriam ^a   Rosenbaum, Eli ^a   Ostrow, Kimberly L ^a   Markova, Alina ^a   Papagerakis, Silvana ^b   Zahurak, Marianna ^a   Goodman, Steven N ^a   Zeiger, Martha ^a   Sidransky, David ^a   Umbricht, Christopher B ^a   Hoque, Mohammad O ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; BRAF; Hypermethylation; RAR 2; RASSF1A; Thyroid cancer; Thyroid tissue; TIMP3

Indexed keywords

ATM PROTEIN; B RAF KINASE; BETA ACTIN; DEATH ASSOCIATED PROTEIN KINASE; GLUTATHIONE TRANSFERASE P1; PROTEIN MLH1; PROTEIN P16; PROTEIN S 100; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; THYROTROPIN RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA2;

ADOLESCENT; ADULT; AGED; AIM1 GENE; ARTICLE; BENIGN TUMOR; CALCA GENE; CONTROLLED STUDY; CTNNB1 GENE; DCC GENE; DNA METHYLATION; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC CORRELATION; HUMAN; KIF1A GENE; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MINT1 GENE; MT1G GENE; NISCH GENE; PAK3 GENE; THBS1 GENE; THYROID CANCER; THYROID TUMOR;

EID: 84863803871     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.20524     Document Type: Article

References (46)

1. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-1159; PMID:18337604; http://dx.doi.org/10.1056/NEJMra072067.
2. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-2054; PMID:14627790; http://dx.doi.org/10.1056/NEJMra023075.
3. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95:625-627; PMID:12697856; http://dx.doi.org/10.1093/jnci/95.8.625.
4. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63:1454-1457; PMID:12670889.
5. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al.; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116:855-867; PMID:15035987; http://dx.doi.org/10.1016/S0092-8674(04)00215-6.
6. Hoque MO, Rosenbaum E, Westra WH, Xing M, Ladenson P, Zeiger MA, et al. Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab 2005; 90:4011-4018; PMID:15840741; http://dx.doi.org/10.1210/jc.2005-0313.
7. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-3229; PMID:11309270.
8. Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, Park HL, et al. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res 2008; 68:2661-2670; PMID:18413733; http://dx.doi.org/10.1158/0008-5472.CAN-07-5913.
9. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-9826; PMID:8790415; http://dx.doi.org/10.1073/pnas.93.18.9821.
10. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31:141-149; PMID:11992124; http://dx.doi.org/10.1038/ng892.
11. Ishida E, Nakamura M, Shimada K, Higuchi T, Takatsu K, Yane K, et al. DNA hypermethylation status of multiple genes in papillary thyroid carcinomas. Pathobiology 2007; 74:344-352; PMID:18087199; http://dx.doi.org/10.1159/000110028.
12. Smith JA, Fan CY, Zou C, Bodenner D, Kokoska MS. Methylation status of genes in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2007; 133:1006-1011; PMID:17938324; http://dx.doi.org/10.1001/archotol.133.10.1006.
13. Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res 2003; 63:2316-2321; PMID:12727856.
14. Guan H, Ji M, Hou P, Liu Z, Wang C, Shan Z, et al. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer 2008; 113:247-255; PMID:18470905; http://dx.doi.org/10.1002/cncr.23548.
15. Huang Y, de la Chapelle A, Pellegata NS. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer 2003; 104:735-744; PMID:12640681; http://dx.doi.org/10.1002/ijc.11006.
16. Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 2006; 119:2322-2329; PMID:16858683; http://dx.doi.org/10.1002/ijc.22110.
17. Nakamura N, Carney JA, Jin L, Kajita S, Pallares J, Zhang H, et al. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest 2005; 85:1065-1075; PMID:15980887; http://dx.doi.org/10.1038/labinvest.3700306.
18. Bello MJ, De Campos JM, Isla A, Casartelli C, Rey JA. Promoter CpG methylation of multiple genes in pituitary adenomas: frequent involvement of caspase-8. Oncol Rep 2006; 15:443-448; PMID:16391867.
19. Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 2004; 64:1664-8; PMID:14996725; http://dx.doi.org/10.1158/0008-5472.CAN-03-3242.
20. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000; 28:32; PMID:10734209; http://dx.doi.org/10.1093/nar/28.8.e32.
21. Virmani AK, Tsou JA, Siegmund KD, Shen LY, Long TI, Laird PW, et al. Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epidemiol Biomarkers Prev 2002; 11:291-297; PMID:11895880.
22. de Bernard S, Misrahi M, Huet JC, Beau I, Desroches A, Loosfelt H, et al. Sequential cleavage and excision of a segment of the thyrotropin receptor ectodomain. J Biol Chem 1999; 274:101-107; PMID:9867816; http://dx.doi.org/10.1074/jbc.274.1.101.
23. Reddy AN, Jiang WW, Kim M, Benoit N, Taylor R, Clinger J, et al. Death-associated protein kinase promoter hypermethylation in normal human lymphocytes. Cancer Res 2003; 63:7694-7698; PMID:14633692.
24. Brait M, Ford JG, Papaiahgari S, Garza MA, Lee JI, Loyo M, et al. Association between lifestyle factors and CpG island methylation in a cancer-free population. Cancer Epidemiol Biomarkers Prev 2009; 18:2984-2991; PMID:19861513; http://dx.doi.org/10.1158/1055-9965.EPI-08-1245.
25. Feil R. Environmental and nutritional effects on the epigenetic regulation of genes. Mutat Res 2006; 600:46-57; PMID:16854438; http://dx.doi.org/10.1016/j.mrfmmm.2006.05.029.
26. Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 2007; 22:91-103; PMID:17284773; http://dx.doi.org/10.1093/mutage/gel068
27. Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10:8472-8478; PMID:15623627; http://dx.doi.org/10.1158/1078-0432.CCR-04-0894.
28. Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Fong K, Gao B, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93:691-699; PMID:11333291; http://dx.doi.org/10.1093/jnci/93.9.691.
29. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, et al. Tumor cellspecific BRCA1 and RASSF1A hypermethylation in serum, plasma and peritoneal fluid from ovarian cancer patients. Cancer Res 2004; 64:6476-6481; PMID:15374957; http://dx.doi.org/10.1158/0008-5472.CAN-04-1529.
30. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25:315-319; PMID:10888881; http://dx.doi.org/10.1038/77083.
31. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang XF, et al. Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 2002; 12:253-265; PMID:11864565; http://dx.doi.org/10.1016/S0960-9822(02)00683-8.
32. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002; 21:1381-1390; PMID:11857081; http://dx.doi.org/10.1038/sj.onc.1205192.
33. Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 2000; 275:35669-35672; PMID:10998413; http://dx.doi.org/10.1074/jbc.C000463200.
34. Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salvesen GS, Bredesen DE. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 1998; 395:801-804; PMID:9796814; http://dx.doi.org/10.1038/27441.
35. Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001; 61:3877-3881; PMID:11358799.
36. Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 2010; 70:1430-1440; PMID:20124475; http://dx.doi.org/10.1158/0008-5472.CAN-09-2755.
37. Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, Czerniak B, et al. Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:2786-2794; PMID:18843024; http://dx.doi.org/10.1158/1055-9965.EPI-08-0192.
38. Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 2002; 22:4309-4318; PMID:12024041; http://dx.doi.org/10.1128/MCB.22.12.4309-18.2002.
39. Hu S, Ewertz M, Tufano RP, Brait M, Carvalho AL, Liu D, et al. Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer. J. Clin Endocrinol Metab 2006; 91:98-104; PMID:16263813; http://dx.doi.org/10.1210/jc.2005-1810.
40. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994; 54:6353-6358; PMID:7987828.
41. Gozuacik D, Bialik S, Raveh T, Mitou G, Shohat G, Sabanay H, et al. DAP-kinase is a mediator of endoplasmic reticulum stress-induced caspase activation and autophagic cell death. Cell Death Differ 2008; 15:1875-1886; PMID:18806755; http://dx.doi.org/10.1038/cdd.2008.121.
42. Li GM, Modrich P. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proc Natl Acad Sci USA 1995; 92:1950-4; PMID:7892206; http://dx.doi.org/10.1073/pnas.92.6.1950.
43. Bolderson E, Scorah J, Helleday T, Smythe C, Meuth M. ATM is required for the cellular response to thymidine induced replication fork stress. Hum Mol Genet 2004; 13:2937-2945; PMID:15459181; http://dx.doi.org/10.1093/hmg/ddh316.
44. Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, Hoque MO, et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 2008; 14:97-107; PMID:18172258; http://dx.doi.org/10.1158/1078-0432.CCR-07-0722.
45. Benoit NE, Goldenberg D, Deng SX, Rosenbaum E, Cohen Y, Califano JA, et al. Colorimetric approach to high-throughput mutation analysis. Biotechniques 2005; 38:635-639; PMID:15884682; http://dx.doi.org/10.2144/05384PF01.
46. SAS/STAT Users Guide. Cary: SAS Institute Inc. 1999.